These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17393737)

  • 1. Clinical trials with allergen products--statistical considerations.
    Volkers P
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):172-80; discussion 181. PubMed ID: 17393737
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical index-score and the ALMA study.
    Bufe A; Holland-Letz T
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):159-65; discussion 165-6. PubMed ID: 17393735
    [No Abstract]   [Full Text] [Related]  

  • 4. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Khan OA; Tselis A; Boster A
    Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to design a clinical trial.
    Curtis BM; Barrett BJ; Parfrey PS
    Methods Mol Med; 2003; 86():475-89. PubMed ID: 12886789
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 14. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.
    Sugimoto T; Sozu T; Hamasaki T
    Pharm Stat; 2012; 11(2):118-28. PubMed ID: 22415870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To throw the baby out with the bathwater: double blinding for specific oral tolerance induction.
    Longo G; Berti I; Barbi E
    Allergy; 2007 Jan; 62(1):82; author reply 83. PubMed ID: 17156347
    [No Abstract]   [Full Text] [Related]  

  • 19. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power and sample size.
    Case LD; Ambrosius WT
    Methods Mol Biol; 2007; 404():377-408. PubMed ID: 18450060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.